Global pharmaceutical and medical devices giant Johnson & Johnson (J&J) has today agreed a £4.9bn deal to acquire Momenta Pharmaceuticals Inc.
J&J revealed that the deal is part of the firm’s plans to expand its portfolio of disease treatments and immunity drugs.
The primary target for the deal was Momenta Pharmaceuitcal’s experimental therapy drug, nipocalimab. It is currently being tested for myasthenia gravis, a neuromuscular disease that causes weakness in muscles, and other diseases where the immune system attacks the body. Nipocalimab will hopefully be used to treat diseases where the body’s own antibodies attack or damage proteins and cells.
Johnson & Johnson said in a statement: “Janssen will have the potential to introduce multiple launches, many as first-in-class indications with potential for significant peak year sales, some of which could exceed $1bn.”
J&J is currently working with the UK and US governments to try and find a vaccine to the current COVID-19 pandemic. Today’s deal is hoped to accelerate those plans, and with other major pharma-giants looking to grow through multi-billion-dollar purchases, this could be a trend the business world will see over the coming months.
This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology.
Autoimmune diseases driven partially or completely by autoantibodies represent a novel area where Janssen can significantly improve health outcomes for patients.
With competitively differentiated, parallel development programs and full worldwide commercial rights for nipocalimab, Janssen will have the potential to introduce multiple launches, many as first-in-class indications with potential for significant peak year sales, some of which could exceed $1bn, supporting Janssen’s goal of continuing to deliver above-market performance over the long term.
“This acquisition broadens Janssen’s leadership in autoimmune diseases and provides us with a major catalyst for sustained growth. Autoantibody-driven diseases are often serious, and patients are underserved by current treatment options,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “We’re excited by the opportunity to further advance patient care by combining Johnson & Johnson’s world-class R&D, commercial and supply chain capabilities with Momenta’s talented people, pipeline and deep expertise in this important area.”